Ankylosing spondylitis (AS) is an inflammatory disease that results in a progressive fusion of some small bones in the spine (vertebrae). This fusion makes the spine less flexible leading to a hunched-forward posture.
At the moment, there are a total of 40 drugs in the pipeline in different phases of development. Interested in knowing more about how the Pharma industry is working to push the drug development and strengthen Ankylosing spondylitis pipeline, download our newsletter by filling up the form towards the right.
The newsletter offers a complete picture of the Ankylosing spondylitis market, pipeline therapies, ongoing clinical trials, Ankylosing spondylitis epidemiological insights, recent happenings in the space, mergers and collaborations, licensing deals along with the events and conferences expected to take place in the coming year.
Subscribe to our mailing list and stay informed about all the recent breakthroughs in the Pharma and Healthcare market.
Get in touch to learn more about our offerings and services.
Know more about What's covered:
- Indication overview
- Signs, symptoms, and diagnosis
- Epidemiological trends
- Treatment approaches
- Clinical trials
- Pipeline drugs
- R&D in the field
- Market insights
- Market Drivers & Barriers
- Unmet needs